Phaseline

Companies › Antelope Surgical Solutions

Antelope Surgical Solutions: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AS1986NS
Fluorescent PSMA imaging agent
–Phase 1Prostate CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06906471AS1986NSPhase 1Prostate CancerOncologyNov 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.